But with seven more Phase 3 trial results expected throughout 2026 and potential approval projected for 2027, it's the drug that weight loss researchers and patients alike are watching most closely
SGLT2 inhibitors represent the most evidence-based pharmacologic therapy that can be readily initiated during hospitalization, whereas agents such as GLP-1 receptor agonists are more appropriately incorporated into outpatient management strategies
[Abstract]2024 Feb 2;10(5):eadj7813
The pathological cutoff value of human plasma TMAO has not yet been concluded and it might benefit by referencing some current literatures [5, 6, 8,9,10]
No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.
However, because the studies differed considerably in how they measured these behaviors and the types of participants they enrolled, the authors caution that the pooled estimate should be interpreted carefully